Michael J. Boivin, PhD, MPH

Professor in Psychiatry and in Neurology & Ophthalmology, Michigan State University;Adjunct Professor in Psychiatry (Neuropsychology Program), University of Michigan, Ann Arbor, USA

Dr. Boivin served as principal investigator in NIMH R34 and NICHD R01 clinical trials evaluation of MISC with HIV-infected and HIV-exposed children and their mothers in Uganda. He will use this clinical trial leadership experience to implement MISC in training moms to better prevent konzo disease in young Congolese children. He is presently a co-investigator with Dr. Desire Tshala-Katumbay (PI: 2R01 ES019841) in the first konzo-prevention cluster RCT clinical trial. Together, They published the first neuropsychological assessments of children affected by konzo disease. Therefore, he is well positioned to adapt MISC in konzo-affected households and communities and assess the neurodevelopmental benefit. He has also co-authored 10 relevant publications on biomarkers of the neuropathogenesis of these neurodevelopmental effects, so he can lead the exploratory analyses of such biomarkers on mapping neurodevelopmental benefits of MISC caregiver training in konzo at-risk children.

Over the past 27 years, Dr. Boivin has pioneered in the application of neuropsychological assessment in gauging the neurocognitive impact of public health risk factors and interventions in African children. This is evidenced most recently by serving as a lead author in an NIH/Fogarty sponsored review of child neurodevelopment and disability in LMICs, recently published in the journal Nature. He was also a co-author on a similar review published at the same time focusing on adolescents. He co-edited the first book published in this field of work, which serves as a compendium of the other major areas of contribution listed below.